Table 1.
Sex | Age | Plaque load | CAA | Braak stage | |||
---|---|---|---|---|---|---|---|
2-48 | 4G8 | Aβ[N] | |||||
Control 1 | M | 74 | + | + | (+) | ✓ | III |
Control 2 | F | 82 | − | − | − | − | I |
Control 3 | F | 73 | − | − | − | ✓ | I |
Control 4 | F | 79 | ++ | ++ | + | ✓ | II |
Control 5 | M | 70 | ++ | +++ | + | − | 0 |
Control 6 | F | 73 | ++ | ++ | (+) | − | 0 |
AD 1 | M | 72 | + | ++ | (+) | − | VI |
AD 2 | M | 70 | +++ | +++ | +++ | ✓ | V |
AD 3 | M | 78 | + | ++ | (+) | ✓ | IV |
AD 4 | M | 60 | +++ | +++ | + | − | VI |
AD 5 | M | 93 | + | + | + | ✓ | IV |
AD 6 | M | 64 | +/++ | ++ | + | ✓ | VI |
AD 7 | F | 77 | ++ | +++ | + | − | VI |
AD 8 | F | 81 | ++ | +++ | + | − | IV |
AD 9 | F | 78 | +++ | +++ | + | − | IV |
AD 10 | F | 64 | (+) | ++ | − | − | III |
AD 11 | F | 88 | +++ | +++ | − | ✓ | IV |
AD 12 | M | 81 | +++ | +++ | +++ | ✓ | IV |
AD 13 | F | 84 | +++ | +++ | − | − | IV |
AD 14 | F | 84 | +++ | +++ | (+) | ✓ | IV |
FAD APP arc | M | 64 | +++ | +++ | +/++ | ✓ | n.a. |
FAD APP swe | F | 61 | +++ | +++ | +++ | ✓ | n.a. |
FAD PS1 P264L | M | 54 | +++ | +++ | (+) | ✓ | VI |
The three familial AD (FAD) patients harbored an APP Swedish mutation (APP swe), an APP arctic mutation (APP arc), and a Presenilin-1 mutation (FAD P264L). Most but not all cases also showed CAA. Antibodies: 4G8 (Aβ 17-24), 2-48 (pGlu Aβ) and Aβ[N] (specific for Aβ at position 1)